The largest number on a probiotic panel can be the least useful starting point for a comparison. One page describes milligrams, another prints a blend in AFU, and a third pairs a mass with CFUs. Their numerical sizes do not establish a common biological scale, even when all three products are capsules.
This guide explains the limits of those declarations without turning them into a calculator. The three-product comparison retains exact source wording, and the organism guide explains the equally separate question of which strains are actually identified. A quantity cannot fill a missing identity, or vice versa.
Keep this distinction in view
No reviewed record supplies a universal conversion among blend weight, colony counts and the printed AFU declaration.
Start with the line to which the amount belongs
CoreAge’s current online Supplement Facts attaches 36 mg to a three-organism blend. Pendulum’s pictured panel attaches 500 million AFU to its probiotic blend. Culturelle’s panel prints 40 mg and 10 billion CFUs beside Lactobacillus rhamnosus GG. The relevant first observation is what each line covers, not which number looks most impressive. The CoreAge review records that its individual organism amounts are not supplied. That missing allocation should remain missing in a comparison. A combined quantity does not become three separate quantities through repetition, and the order of names does not supply an unpublished assay result. CoreAge Pendulum Culturelle
Mass is not a viable-cell count
Milligrams describe weight. They do not, by themselves, establish the number of viable organisms, the proportion contributed by a particular strain or the result of a microbial counting method. Culturelle’s paired mass and CFU declaration is a statement about its own named preparation. It cannot be used as a ratio to calculate a count from CoreAge’s unrelated blend weight. NIH discusses probiotic products and count information in the context of their specific organisms and labels. The finished-formula guide explains why differences in formulation also matter to interpreting research. A conversion invented from another product would conceal the uncertainty instead of resolving it. NIH Culturelle declaration
CFU needs a product and time-point context
NIH discusses colony-forming-unit information and notes the importance of counts through the expiry or use-by date rather than only at manufacture. A number printed without its basis can leave a reader uncertain about what is being represented. Culturelle separately conditions its potency guarantee on the date on the box and storage as directed. That manufacturer statement is more specific than a number alone, but this publication has not tested a delivered lot or its storage history. The Culturelle review preserves that boundary. A count guarantee is not a promise of a clinical benefit, and it should not be translated into a personal amount to take. NIH label discussion Culturelle
AFU remains the declaration actually shown
Pendulum’s inspected image prints AFU. It does not show a conversion factor to the CFU number on Culturelle’s panel. The public ISO 19344:2015 abstract describes quantifying active and/or total bacteria by flow cytometry within a stated dairy-starter, probiotic and fermented-milk scope. It also describes limits, including the lack of taxonomic differentiation and possible counting of other bacteria. That abstract is useful method context, not proof of which assay Pendulum used. The Pendulum review therefore reports AFU as printed rather than manufacturing a comparable CFU value. A manufacturer method statement would still need its own scope and supporting documentation. Pendulum panel ISO abstract
Methods and legal descriptions are separate documents
ISO’s explanatory article describes flow cytometry and traditional plate-count approaches in the setting of the standard. It does not certify these three retail products. FDA’s September 2018 document on live-microbial quantity labeling is expressly a draft, marked not for implementation, and describes proposed enforcement discretion for CFU declarations alongside weight under conditions. A review should preserve that status rather than present the draft as a final rule or use it to declare a particular label unlawful. The question here is what the documents establish, not a legal judgment about a seller. Neither source supplies a universal formula that makes the different printed quantities equivalent. ISO explanation FDA draft
A count cannot choose the relevant outcome
Even a clearly identified strain and a well-described count do not tell a reader which condition or outcome was studied. NIH emphasizes that probiotic evidence can be strain-specific, and study design still matters. A large number cannot turn a consumer survey into a controlled trial, or make a glucose-related endpoint into proof of relief from prescription adverse effects. The evidence-design guide addresses that next step. These are reasons to keep identity, measurement and outcomes in separate sentences. Combining them into a single strength score would make the page easier to rank while making the scientific claim harder to justify. NIH evidence framework
Leave the unanswered measurement visible
Questions for a manufacturer can name the unit, assay method, organisms included, whether the total is combined, and the time point represented. Those requests concern a record, not a personal dose. Questions about whether any studied preparation is relevant to actual care belong with a qualified health professional. The fixed source reader offers examples without collecting personal information or performing calculations. NCCIH describes ongoing uncertainties about which probiotics help, in which circumstances, and about safety in some populations. A clearer label can improve an evidence conversation, but it cannot itself grant eligibility, resolve medicine interactions or replace medical assessment. NCCIH
Sources for this article
CoreAge Rx: GLP-1 Support current offer and online Supplement Facts
Fresh seller formula and full offer record; inspected bottle front only, no physical back panel, lot assay or transaction verification
Checked 2026-09-28
https://try.coreagerx.com/glp-supp-spPendulum: GLP-1 Probiotic current product and facts image
Fresh product record and actually inspected current pictured panel; two visible strain codes, combined AFU declaration and attributed six-week consumer survey, not a supplied-lot test
Checked 2026-09-28
https://pendulumlife.com/products/glp-1-probiotic-for-cravingsCulturelle: US Digestive Daily Probiotic Capsules
Fresh exact US product page plus two inspected official facts images; general digestive product, not GLP-1-specific branding or universal clinical indication
Checked 2026-09-28
https://culturelle.com/products/digestive-daily-probioticNIH Office of Dietary Supplements: Probiotics, Health Professional Fact Sheet
Federal evidence review for organism nomenclature, strain-specific clinical context, mechanisms and quantities; no product or patient clearance
Checked 2026-09-28
https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ISO 19344:2015: public standard abstract
Public abstract, edition December 2015, reviewed and confirmed in 2026; dairy-related flow-cytometry scope and limits, not reviewed-product certification or proof of a seller assay
Checked 2026-09-28
https://www.iso.org/standard/64658.htmlISO: New standard speeds up quality control and facilitates trade of probiotics and starter cultures, 2016
Issuer explanation of the stated method and scope; no AFU-to-CFU exchange rate or product-specific validation
Checked 2026-09-28
https://www.iso.org/news/2016/01/Ref2045.htmlFDA: Draft Guidance on Quantitative Labeling of Live Microbials, September 2018
Expressly DRAFT, not for implementation, nonbinding recommendations; no final-rule or product-legality inference
Checked 2026-09-28
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-policy-regarding-quantitative-labeling-dietary-supplements-containing-liveNCCIH: Probiotics, Usefulness and Safety
Federal evidence and safety uncertainties; professional-care boundary, no personal regimen or delay of clinical care
Checked 2026-09-28
https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety